BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bambusa Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Bambusa Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07717905-1309@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BBT001: Phase 1/2 readout est. (NCT07717905)
DESCRIPTION:BBT001\, phase 1/2.\nStudy: A Study to Evaluate the Safety\, To
 lerability\, Pharmacokinetics\, Immunogenicity\, Pharmacodynamics and Clin
 ical Activity of BBT001 Following Intravenous Administration in Participan
 ts With Chronic Spontaneous Urticaria (CSU)\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bb
 t001#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07717905
URL:https://assetmemo.bio/drug/bbt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436949-1540@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BBT002: Phase 1/2 readout est. (NCT07436949)
DESCRIPTION:BBT002\, phase 1/2.\nStudy: A Study of BBT002 in Healthy Volunt
 eers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (
 CRSwNP) With or Without Comorbid Asthma\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bbt002
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 36949
URL:https://assetmemo.bio/drug/bbt002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
